ProCE Banner Activity

Phase III LyMa Trial: Post-ASCT Rituximab Maintenance Increases Survival for Younger Patients With Mantle Cell Lymphoma

Slideset Download
Conference Coverage
Maintenance rituximab after ASCT prolongs EFS, PFS, and OS for younger patients with mantle cell lymphoma vs observation only.

Released: December 06, 2016

Expiration: December 05, 2017

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

Amgen, Inc.

Celgene

Incyte

Merck & Co., Inc.

Seagen